Related Experiment Videos
Management of paediatric lymphoma
T Philip1, C Bergeron, D Frappaz
1Centre Leon Berard, Lyon, France.
Bailliere'S Clinical Haematology
|December 1, 1996
Summary
High cure rates in childhood lymphomas offer optimistic treatment outlooks, with reduced late effects like cognitive impairment and reproductive issues. Further research is needed to fully understand long-term outcomes and treatment impacts on fertility and second malignancy risks.
Area of Science:
- Pediatric Oncology
- Hematology
- Clinical Genetics
Background:
- Paediatric lymphomas demonstrate high cure rates, leading to improved long-term prognoses for survivors.
- While radiation therapy's neurocognitive effects are known, high-dose methotrexate's long-term impacts require further study.
- Male reproductive function is more susceptible to treatment toxicity than female reproductive function.
Purpose of the Study:
- To review the late effects of paediatric lymphoma treatments, focusing on neurocognitive function, reproductive health, and secondary malignancy risks.
- To discuss the evolving understanding of treatment-related toxicities and their long-term implications for childhood cancer survivors.
- To highlight the importance of molecular biology advancements in refining lymphoma classification and guiding future therapeutic strategies.
Main Methods:
- Review of existing literature on treatment outcomes and late effects in paediatric lymphoma patients.
- Analysis of data regarding the dose-dependent toxicity of specific chemotherapeutic agents, such as cyclophosphamide.
- Exploration of the role of molecular biology in characterizing lymphoma subtypes and informing treatment decisions.
Main Results:
- High cure rates are achievable, but late effects such as cognitive impairment and reproductive dysfunction persist.
- Alkylating agents, particularly cyclophosphamide, show significant dose-dependent toxicity to male fertility.
- The risk of second malignancies is elevated with alkylating agent use, though generally lower than in solid tumors or Hodgkin's disease.
Conclusions:
- Long-term follow-up is crucial for understanding the full spectrum of late effects and refining treatment protocols.
- Advances in molecular biology are key to personalized medicine, enabling distinct therapeutic approaches for low- and high-risk patients.
- Future goals include intensifying chemotherapy for high-risk cases (CNS/bone marrow involvement) and reducing treatment burden for good-prognosis patients.